Stock A156100 L&K BIOMED LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials L&K Biomed Ltd.

Equities

A156100

KR7156100000

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-06-03 EDT 		5-day change 1st Jan Change
10,090 KRW +0.20% Intraday chart for L&K Biomed Ltd. +6.77% -0.88%
05-09 L&K Biomed Ltd. announced that it has received KRW 20 billion in funding from a group of investors CI
05-07 L&K Biomed Ltd. announced that it expects to receive KRW 20 billion in funding from a group of investors CI

Valuation

Fiscal Period: December 2019 2020 2022 2023 2024 2025
Capitalization 1 73,024 505,923 107,379 202,956 201,162 -
Enterprise Value (EV) 2 73.02 517.8 107.4 203 208.6 192.2
P/E ratio -6.63 x -39.6 x -7.88 x -88.5 x 21.9 x 10.3 x
Yield - - - - - -
Capitalization / Revenue - 27.3 x - 6.79 x 3.29 x 2.13 x
EV / Revenue - 27.9 x - 6.79 x 3.41 x 2.03 x
EV / EBITDA - -815 x - 46.7 x 14.2 x 6.89 x
EV / FCF - -190 x - - 30.2 x 16.6 x
FCF Yield - -0.53% - - 3.31% 6.04%
Price to Book - 9.68 x - - 8.42 x 4.64 x
Nbr of stocks (in thousands) 10,417 12,906 13,406 19,937 19,937 -
Reference price 3 7,010 39,200 8,010 10,180 10,090 10,090
Announcement Date 20-03-30 21-02-24 23-03-16 24-03-12 - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2022 2023 2024 2025
Net sales 1 - 18.54 - 29.9 61.2 94.5
EBITDA 1 - -0.6351 - 4.348 14.7 27.9
EBIT 1 - -3.716 - 2.034 12.3 25.4
Operating Margin - -20.05% - 6.8% 20.1% 26.88%
Earnings before Tax (EBT) 1 - -10.07 - -6.517 11.9 26
Net income 1 -11.03 -11.76 -13.63 -5.289 9.2 19.4
Net margin - -63.44% - -17.68% 15.03% 20.53%
EPS 2 -1,058 -989.0 -1,017 -115.0 460.0 975.0
Free Cash Flow 3 - -2,721 - - 6,900 11,600
FCF margin - -14,678.01% - - 11,274.51% 12,275.13%
FCF Conversion (EBITDA) - - - - 46,938.78% 41,577.06%
FCF Conversion (Net income) - - - - 75,000% 59,793.81%
Dividend per Share - - - - - -
Announcement Date 20-03-30 21-02-24 23-03-16 24-03-12 - -
1KRW in Billions2KRW3KRW in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2022 2023 2024 2025
Net Debt 1 - 11.9 - - 7.4 -
Net Cash position 1 - - - - - 9
Leverage (Debt/EBITDA) - -18.72 x - - 0.5034 x -
Free Cash Flow 2 - -2,721 - - 6,900 11,600
ROE (net income / shareholders' equity) - -20.6% - -25.6% 47.6% 57.9%
ROA (Net income/ Total Assets) - -10.2% - - 17.3% 28.8%
Assets 1 - 115 - - 53.18 67.36
Book Value Per Share 3 - 4,048 - - 1,198 2,173
Cash Flow per Share - - - - - -
Capex 1 - 1.94 - - 2.8 3.4
Capex / Sales - 10.49% - - 4.58% 3.6%
Announcement Date 20-03-30 21-02-24 23-03-16 24-03-12 - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for L&K Biomed Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Medical Devices & Implants

1st Jan change Capi.
L&K BIOMED LTD. Stock L&K Biomed Ltd.
-0.88% 146M
STRYKER CORPORATION Stock Stryker Corporation
+14.21% 129B
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-7.72% 10.98B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
-1.95% 8.22B
GLAUKOS CORPORATION Stock Glaukos Corporation
+40.43% 5.76B
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
-27.04% 4.41B
AXONICS, INC. Stock Axonics, Inc.
+7.47% 3.41B
ENOVIS CORPORATION Stock Enovis Corporation
-15.26% 2.7B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-12.01% 2.1B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-13.56% 1.91B
Medical Devices & Implants
  1. Stock Market
  2. Equities
  3. A156100 Stock
  4. Financials L&K Biomed Ltd.